Solara Active Pharma Sciences posts Q2 FY26 consolidated loss at Rs. 10.10 Cr

Solara Active Pharma Sciences has reported total income of Rs. 314.03 crore during the period ended September 30, 2025

Caplin Point Laboratories reports Q2 FY26 consolidated PAT at Rs. 154.45 Cr

Caplin Point Laboratories has reported total income of Rs. 564.41 crore during the period ended September 30, 2025

Zydus Lifesciences secures FDA tentative approval for Olaparib tablets

Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers

AstraZeneca invests additional $136 million to expand Qingdao inhalants facility

This latest commitment brings the British pharmaceutical company’s total investment at the site to $886 million

Sovato secures series B funding to advance remote robotic surgery platform

The company plans to use the funds to enhance its technology and forge new strategic partnerships with surgical robotics companies

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Amgen confident in US biosimilar market’s strength as sales surge 52%

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies

UPS acquires Andlauer for $1.6 billion to strengthen global healthcare network

The integration of AHG’s specialized cold chain transportation and third-party logistics (3PL) solutions will significantly strengthen UPS Healthcare’s service offerings

EazeBio and UC Santa Cruz partner to advance instrument-free diagnostic platform

Collaboration aims to deliver rapid, lab-quality testing to communities worldwide – making precision health more accessible